Key considerations in reimbursement decision-making for multiple sclerosis drugs in Australia.

Background: In Australia, the Pharmaceutical Benefits Advisory Committee (PBAC) advises on the reimbursement of drugs to be subsidised through the Pharmaceutical Benefits Scheme (PBS). This study aims to provide insights into the PBAC process and key considerations regarding the reimbursement of MS drugs in Australia.

Methods: The factors considered by the PBAC and its advice on whether to reimburse a drug are documented in public summary documents (PSDs).